로딩 중…
지수 로딩 중…
ImmunityBio, Inc.
IBRX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$7.15-0.28%
2026-08-03
Financials
Valuation Metrics
ImmunityBio, Inc.'s Market Cap is $7.49B. At end of 2025 it was $1.96B. Ranked #1119 of 3,112 in US market (top 36%), #366 of 1,445 on NASDAQ (top 25%), #59 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 22%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $7.49B | US#1,119/3,112 Sec#59/269 |
| Revenue | $141M | US#2,741/3,112 Sec#119/269 |
| Net Income | $-855M | US—/3,112 Sec—/269 |
| Total Assets | $647M | US#2,649/3,112 Sec#133/269 |
| Net Assets | $-870M | US#3,043/3,112 Sec#270/269 |
| Value | ||
| P/S | 53.12x | US#2,879/3,112 Sec#169/269 |
| FCF Yield | -4.00% | US—/3,112 Sec—/269 |
| Profitability | ||
| Op. Margin | -185.41% | US#2,853/3,112 Sec#133/269 |
| Revenue Growth | 167.64% | US#81/3,112 Sec#24/269 |
| Financial Health | ||
| Total Debt | $1.12B | US#1,424/3,112 Sec#41/269 |
| FCF | $-299M | US#2,785/3,112 Sec#238/269 |
| Cash | $205M | US#1,707/3,112 Sec#113/269 |
| Current Ratio | 6.67x | US#360/3,112 Sec#116/269 |
| Performance | ||
| 1Y Return | 201.69% | US#108/3,112 Sec#35/269 |
| 1M Return | -24.26% | US#3,009/3,112 Sec#243/269 |
| From 52W High | -42.48% | US#2,610/3,112 Sec#203/269 |
| 1Y MDD | -42.44% | US#2,070/3,112 Sec#153/269 |
| Trading | ||
| Volume | 8,467,711 shares | US#207/3,112 Sec#15/269 |
| Trading Value | $61M | US#1,228/3,112 Sec#71/269 |
| Per Share | ||
| EPS | $-0.36 | US—/3,112 Sec—/269 |